… K. Diedrich 4 … (Centre of Reproductive Medicine, Dutch-speaking Brussels Free University),
Klaus Diedrich (University Hospital of Schleswig-Holstein, Lübeck, Germany), Aliza Eshkol (…

This systematic review and meta-analysis aimed to answer the following clinical question:
among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of …

The present review describes, on the basis of the currently available evidence, the
consensus reached by a group of experts on the use of gonadotropin-releasing hormone (GnRH) …

Background Early improvements in disease-free survival have been noted when an aromatase
inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal …

Surges of luteinizing hormone (LH) that result In luteinization but occur prematurely with
respect to the diameter of the leading folilde, prevent attempts to induce multiple follicular …

In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing
hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin …

Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during
ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of …

Three different methods were used for freezing human excess oocytes (320 frozen, 205
thawed) in our IYF programmme and the results of these methods weax compared. A high …

BACKGROUND: Eliciting an endogenous LH surge by GnRH-agonist for the induction of
final oocyte maturation may be more physiological compared with the administration of HCG. …

Breast cancer is a major cause of cancer‐related death in women. BRCA1 tumour‐suppressor
function is abolished in sporadic breast cancer by down‐regulation of the protein level. …